Systemic light chain amyloidosis (LCA) is a rare monoclonal B cell disorder characterized by the accumulation of misfolded monoclonal light chain fragments within the heart, kidney, liver, gut, peripheral nerves, and other tissues, resulting in damage to these organs. Median survival is poor (less than 3 years in many series) and most closely associated with the degree of cardiac involvement [1-5]. However, recent progress in the diagnosis, characterization, and management of patients with LCA necessitates thoughtful reassessment of the role of high-dose chemotherapy in the management of this challenging disease.
No takes yet. Share an insight, caveat, or question.
Steven Michael Devine (2013) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: